Grufity logoGrufity logo

GKOS

44.05USD-1.83(-3.99%)Market Closed

Glaukos Corp

Market Summary

USD44.05-1.83Market Closed
-3.99%

GKOS Alerts

GKOS Stock Price

RSI Chart

Valuation

Market Cap

2.7B

Price/Earnings

-49.26

Price/Sales

9.53

Price/Cashflow

256.91

MarketCap/EBT

-49.31

Price/Sales

Profitability

EBT Margin

-19.33%

Return on Equity

-9.92%

Return on Assets

-5.41%

Fundamentals

Revenue

Revenue (TTM)

284.9M

Revenue Y/Y

-4.61%

Revenue Q/Q

-1.95%

Earnings

Earnings (TTM)

-89.6M

Earnings Y/Y

-542.63%

Earnings Q/Q

39.44%

Price Action

52 Week Range

33.3364.49
(Low)(High)

Last 7 days

-3.4%

Last 30 days

-9.5%

Last 90 days

-22.7%

Trailing 12 Months

6.3%

Financial Health

Current Ratio

6.78

Debt/Equity

0.01

Debt/Cashflow

8.13

Investor Care

Shares Dilution (1Y)

1.73%

Diluted EPS (TTM)

-1.9

Peers (Alternatives to Glaukos)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-15.19% 31.17%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
11.64% -6.61%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
11.18% -17.75%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.66% 2.81%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
8.58% 10.96%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
5.44% -35.45%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
9.55% 2.62%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.31% -13.25%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-6.98% -2.00%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
14.84% -68.69%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
23.76% 23.16%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
2.27% -17.18%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
15.03% -14.89%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-5.60% -30.91%
-16.43
2.57
-8.79% -175.19%

Financials for Glaukos

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-1.2%285288294294294
Gross Profit-2.2%216221227227225
Operating Expenses10.9%283255238260251
  S&GA Expenses1.4%189186181179175
  R&D Expenses-108
Earnings Before Taxes-60.6%-89.50-55.74-27.37-49.27-40.92
Net Income-60.6%-89.61-55.80-27.75-49.59-38.37
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-2.2%1,0081,0311,0521,0501,064
  Current Assets-4.7%449471491486502
    Cash Equivalents1.4%104103106101113
  Inventory22.8%3428252320
  Net PPE7.9%8781756961
  Goodwill0%6666666666
Liabilities-1.9%460469455463463
  Current Liabilities-12.8%6170566363
Shareholder's Equity-2.5%549562598587601
  Retained Earnings-6.8%-432.95-405.37-359.83-365.21-343.34
  Additional Paid-In Capital1.4%985972961952943
Accumulated Depreciation-21----
Shares Outstanding0.5%4847474747
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-414.1%-33.6111302540
  Share Based Compensation10.4%3431283032
Cashflow From Investing161.7%19-31.20-42.87-58.23-52.82
Cashflow From Financing4.8%77233946

Risks

What is the probability of a big loss on GKOS?

97.3%


Probability that Glaukos stock will be more than 20% underwater in next one year

67.3%


Probability that Glaukos stock will be more than 30% underwater in next one year.

49.6%


Probability that Glaukos stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GKOS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Glaukos was unfortunately bought at previous high price.

Returns

Cumulative Returns on GKOS

9.4%


7-Year Cumulative Returns

11.2%


5-Year Cumulative Returns

-9.8%


3-Year Cumulative Returns

What are the long-term rolling returns for GKOS?

FIve years rolling returns for Glaukos.

Which funds bought or sold GKOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,794,000
1,794,000
0.02%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.77
411,000
3,130,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-79,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
UNCHANGED
-
3,000
22,000
-%
2022-11-15
State of Tennessee, Treasury Department
UNCHANGED
-
-
1,463,000
0.01%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
0.15
539,000
3,639,000
-%
2022-11-15
Balyasny Asset Management LLC
REDUCED
-7.71
1,813,000
23,973,000
0.07%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
49,000
333,000
-%
2022-11-15
NOMURA HOLDINGS INC
REDUCED
-53.01
-11,099,000
12,357,000
0.05%

1–10 of 40

Latest Funds Activity

Are funds buying GKOS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own GKOS

Glaukos News

Best Stocks

Brokerages have given Glaukos Co. (NYSE:GKOS) an average rating of "Hold.".11 hours ago

GKOS Fair Value

Recent SEC filings of Glaukos

View All Filings
Date Filed Form Type Document
Nov 15, 2022
8-K
Current Report
Nov 04, 2022
10-Q
Quarterly Report
Nov 02, 2022
8-K
Current Report
Sep 07, 2022
8-K
Current Report

Latest Insider Trading transactions for GKOS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-19
Kliman Gilbert H
SOLD
-
-
-2,382
-
2022-08-19
Kliman Gilbert H
ACQUIRED
-
-
2,382
-
2022-08-05
Kliman Gilbert H
SOLD
-178,229
53.0129
-3,362
-
2022-08-04
Kliman Gilbert H
SOLD
-
-
-333,917
-
2022-08-04
Kliman Gilbert H
SOLD
-
-
-83,955
-
2022-08-04
Kliman Gilbert H
ACQUIRED
-
-
83,955
-
2022-08-04
Kliman Gilbert H
ACQUIRED
-
-
19,045
-
2022-06-02
WEISNER AIMEE S
ACQUIRED
-
-
4,364
-
2022-06-02
Foley Mark J
ACQUIRED
-
-
4,364
-
2022-06-02
Kliman Gilbert H
ACQUIRED
-
-
4,364
-

1–10 of 50

Thomas W. Burns
730
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

GKOS Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Net sales$ 71,269$ 74,710$ 211,635$ 220,771
Cost of sales16,86115,37051,75749,762
Gross profit54,40859,340159,878171,009
Operating expenses:    
Selling, general and administrative47,14944,470140,998131,691
Research and development28,87028,84687,45974,321
In-process research and development 5,00010,00010,000
Litigation-related settlement (30,000)(30,000)(30,000)
Total operating expenses76,01948,316208,457186,012
(Loss) income from operations(21,611)11,024(48,579)(15,003)
Non-operating expense:    
Interest income7442911,4151,016
Interest expense(3,481)(3,413)(10,311)(9,948)
Other expense, net(2,981)(1,470)(9,792)(3,097)
Total non-operating expense(5,718)(4,592)(18,688)(12,029)
(Loss) income before taxes(27,329)6,432(67,267)(27,032)
Income tax provision247202468689
Net (loss) income$ (27,576)$ 6,230$ (67,735)$ (27,721)
Basic net (loss) income per share (in dollar per share)$ (0.58)$ 0.13$ (1.43)$ (0.60)
Diluted net (loss) income per share (in dollar per share)$ (0.58)$ 0.13$ (1.43)$ (0.60)
Weighted average shares used to compute basic net (loss) income per share47,61446,73747,34646,255
Weighted average shares used to compute diluted net (loss) income per share47,61449,32047,34646,255

GKOS Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 104,018$ 100,708
Short-term investments257,600313,343
Accounts receivable, net34,76633,438
Inventory34,18223,011
Prepaid expenses and other current assets18,27515,626
Total current assets448,841486,126
Restricted cash9,0789,416
Property and equipment, net87,30768,969
Operating lease right-of-use assets26,04928,142
Finance lease right-of-use asset47,20649,022
Intangible assets, net314,097332,781
Goodwill66,13466,134
Deposits and other assets9,7569,108
Total assets1,008,4681,049,698
Current liabilities:  
Accounts payable11,4657,333
Accrued liabilities49,15056,027
Total current liabilities60,61563,360
Convertible senior notes281,056280,026
Operating lease liability29,12929,650
Finance lease liability72,31972,699
Deferred tax liability, net7,3017,318
Other liabilities9,4949,494
Total liabilities459,914462,547
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 150,000 shares authorized; 47,693 and 46,993 shares issued and 47,665 and 46,965 shares outstanding as of September 30, 2022 and December 31, 2021, respectively4847
Additional paid-in capital985,407952,432
Accumulated other comprehensive (loss) income(3,823)15
Accumulated deficit(432,946)(365,211)
Less treasury stock (28 shares as of September 30, 2022 and December 31, 2021)(132)(132)
Total stockholders' equity548,554587,151
Total liabilities and stockholders' equity$ 1,008,468$ 1,049,698